HDFC Securities' research report on Balaji Amines
Both EBITDA and APAT were 40% above our estimates largely due to better sales mix. Higher sales volumes of high margin amines derivatives and specialty products has resulted in better gross margin of 48.2% (est. 44.4%). Besides, sales volumes were 4.7% more than expected.
Outlook
Our BUY recommendation on Balaji Amines with a TP of INR 560 owing to (1) Robust demand from pharma and agrochemical industry that comprise ~70% of its revenue mix, and (2) Faster than anticipated recovery in plant utilisation as demand bounces back post the Covid-19 pandemic.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.